Previous 10 | Next 10 |
Emerging preclinical and clinical literature support MSCs may be appropriate to develop for COVID-19 as well as non-COVID-19 ARDS ImStem’s investigational MSC candidate IMS001, for which FDA recently removed a clinical hold on an IND to begin a human study in multiple sclerosis,...
Sernova to utilize AgeX’s UniverCyte TM gene technology to generate transplantable, universal immune-protected therapeutic cells for Sernova’s Cell Pouch TM Platform AgeX Therapeutics, Inc. (“AgeX”: NYSE American: AGE), a biotechnology company developing the...
AgeX Therapeutics , Inc. (“AgeX”: NYSE American: AGE), a biotechnology company developing therapeutics for human aging and regeneration, announced today that Andrea Park has been appointed Chief Financial Officer. Ms. Park replaces Russell Skibsted who served in that role sinc...
AgeX Therapeutics (NYSEMKT: AGE ): Q1 GAAP EPS of -$0.08. More news on: AgeX Therapeutics, Inc., Earnings news and commentary, , Read more ...
AgeX Therapeutics , Inc. (“AgeX”: NYSE American: AGE), a biotechnology company developing therapeutics for human aging and regeneration, reported financial and operating results for the first quarter ended March 31, 2020. “The human tragedy of this pandemic has long...
AgeX Therapeutics , Inc. (“AgeX”; NYSE American: AGE), a biotechnology company developing therapeutics for human aging and regeneration, announced that based on a strategic review of its operations, giving consideration to the status of its product development programs, human r...
AgeX Therapeutics ( AGE ) is an interesting company in the up-and-coming longevity space. This article will take a look at the science behind their current development programs as well as the leading figures and stakeholders in the company. AgeX is certainly a very risky bet, both because of t...
AgeX Therapeutics (NYSEMKT: AGE ): FY GAAP EPS of -$0.33. More news on: AgeX Therapeutics, Inc., Earnings news and commentary, , Read more ...
Entered research collaboration with Japanese biopharma company to generate hypoimmunogenic cells Formed collaboration with UC Irvine on neural stem cell research program for Huntington’s disease and other neurological disorders First ever clearance of cell therapy deriv...
AgeX Therapeutics , Inc. (“AgeX”; NYSE American: AGE), a biotechnology company focused on developing therapeutics for human aging and regeneration, announced today that ImStem Biotechnology, Inc. (Farmington, CT), a biopharmaceutical company pioneering the development of mesenc...
News, Short Squeeze, Breakout and More Instantly...
Shares of Serina to commence trading on NYSE American under the ticker symbol “SER” on March 27, 2024 Lead candidate SER-252, POZ-apomorphine preclinical studies anticipated to be completed in the fourth quarter of 2024; IND submission to the FDA for the initiation of a Phas...
ALAMEDA, Calif., March 22, 2024 (GLOBE NEWSWIRE) -- AgeX Therapeutics, Inc. (“AgeX”; NYSE American: AGE), a biotechnology company developing therapeutics for human aging and regeneration, reported its financial and operating results for fourth quarter and the full year ended Decembe...
A look at the top 10 most actives in the United States Verb Technology Company Inc. (VERB) rose 211.4% to $0.4422 on volume of 532,901,553 shares Fisker Inc. Class A (FSR) rose 12.8% to $0.1747 on volume of 376,460,729 shares Better Therapeutics Inc. (BTTX) rose 27.4% to $0.0446 on volume...